A year of generic PrEP could recoup its own cost within five years if effectiveness is high, Public Health England model finds
PrEP would save the NHS money, in numerous scenarios
New US PrEP cost-effectiveness model finds drug prices will need to drop substantially if HIV risk rises, or if adherence is only moderate
No evidence of reduced efficacy or increased side-effects when patients switch to generic drugs, comparison study finds
US HIV funding decisions on PEPFAR in 2017 will have critical effect on ability to reach 90-90-90 goals
Countries and donors should aim for new $90-$90-$90 target on HIV, hepatitis, TB drug prices, study shows
Investment in harm reduction for people who use drugs – new research reveals critical shortfalls in some European countries
Switching from Atripla to generic-containing regimens can produce large cost savings
When science, community and political will come together, we can end the epidemic, says New York commissioner
